These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28636806)

  • 21. Laromustine (cloretazine).
    Vey N; Giles F
    Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients.
    Nassar AF; Wisnewski AV; King I
    Xenobiotica; 2017 May; 47(5):394-407. PubMed ID: 27440490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine (KS119): a cytotoxic prodrug with two stable conformations differing in biological and physical properties.
    Penketh PG; Baumann RP; Shyam K; Williamson HS; Ishiguro K; Zhu R; Eriksson ES; Eriksson LA; Sartorelli AC
    Chem Biol Drug Des; 2011 Oct; 78(4):513-26. PubMed ID: 21777394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carbonyl]hydrazine: an anticancer agent targeting hypoxic cells.
    Seow HA; Penketh PG; Shyam K; Rockwell S; Sartorelli AC
    Proc Natl Acad Sci U S A; 2005 Jun; 102(26):9282-7. PubMed ID: 15964988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2- chloroethyl)hydrazines as antineoplastic agents.
    Shyam K; Penketh PG; Divo AA; Loomis RH; Rose WC; Sartorelli AC
    J Med Chem; 1993 Nov; 36(23):3496-502. PubMed ID: 8246218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models.
    Zheng LM; Li Z; Liu L; Song BL; King I
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):45-51. PubMed ID: 17256135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KS900: A hypoxia-directed, reductively activated methylating antitumor prodrug that selectively ablates O(6)-alkylguanine-DNA alkyltransferase in neoplastic cells.
    Baumann RP; Ishiguro K; Penketh PG; Shyam K; Zhu R; Sartorelli AC
    Biochem Pharmacol; 2011 May; 81(10):1201-10. PubMed ID: 21396917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of 1,2,2-tris(sulfonyl)hydrazines as antineoplastic and trypanocidal agents.
    Shyam K; Penketh PG; Divo AA; Loomis RH; Patton CL; Sartorelli AC
    J Med Chem; 1990 Aug; 33(8):2259-64. PubMed ID: 2374151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme.
    Badruddoja MA; Penne K; Desjardins A; Reardon DA; Rich JN; Quinn JA; Sathornsumetee S; Friedman AH; Bigner DD; Herndon JE; Cahill A; Friedman HS; Vredenburgh JJ
    Neuro Oncol; 2007 Jan; 9(1):70-4. PubMed ID: 17108065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biotransformation and Rearrangement of Laromustine.
    Nassar AE; Wisnewski AV; King I
    Drug Metab Dispos; 2016 Aug; 44(8):1349-63. PubMed ID: 27278961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male rats.
    Nassar AF; Wisnewski A; King I
    Xenobiotica; 2015; 45(8):711-21. PubMed ID: 25798740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cloretazine for the treatment of acute myeloid leukemia.
    Vey N; Giles F
    Expert Rev Anticancer Ther; 2006 Mar; 6(3):321-8. PubMed ID: 16503849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin.
    Morris KL; Adams JA; Liu Yin JA
    Leuk Res; 2009 Aug; 33(8):1096-9. PubMed ID: 19268363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical evaluation of Laromustine for use in combination with radiation therapy in the treatment of solid tumors.
    Rockwell S; Liu Y; Seow HA; Ishiguro K; Baumann RP; Penketh PG; Shyam K; Akintujoye OM; Glazer PM; Sartorelli AC
    Int J Radiat Biol; 2012 Mar; 88(3):277-85. PubMed ID: 22111842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice.
    Badruddoja MA; Keir ST; King I; Zeidner J; Vredenburgh JJ; Muhlbaier LH; Bigner DD; Friedman HS
    Neuro Oncol; 2007 Jul; 9(3):240-4. PubMed ID: 17522334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
    Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
    Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and analysis of activity of a potential anti-melanoma prodrug with a hydrazine linker.
    Frąckowiak-Wojtasek B; Gąsowska-Bajger B; Mazurek M; Raniszewska A; Logghe M; Smolarczyk R; Cichoń T; Szala S; Wojtasek H
    Eur J Med Chem; 2014 Jan; 71():98-104. PubMed ID: 24287558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia.
    Rizzieri D; LoRusso S; Tse W; Khan K; Advani A; Moore J; Karsten V; Cahill A; Gerson SL
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):211-6. PubMed ID: 20511167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acyloxymethyl as a drug protecting group. Part 6: N-acyloxymethyl- and N-[(aminocarbonyloxy)methyl]sulfonamides as prodrugs of agents containing a secondary sulfonamide group.
    Lopes F; Moreira R; Iley J
    Bioorg Med Chem; 2000 Apr; 8(4):707-16. PubMed ID: 10819159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas.
    Penketh PG; Shyam K; Sartorelli AC
    Biochem Pharmacol; 2000 Feb; 59(3):283-91. PubMed ID: 10609557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.